Edmund is co-founder and CEO of Apertor Pharmaceuticals and leads to company in bringing a new modality, Interceptors, to help cancer patients. Previously, he directed research programs at Pfizer and Wyeth involving (i) the synthetic biology of ‘beyond-rule-of-five’ compounds, (ii) conjugation of small molecules to antibodies to make antibody-drug conjugates (ADCs) for oncology indications at and co-invented multiple ADCs , and (iii) leading matrix teams to advance semi-synthetic natural products from early discovery to first-in-human (FIH) for programs in neuroscience (ILS-920 for ischemic stroke) and inflammation (MS/lupus).